Ingress-Health publishes analysis about bDMARD drug survival in rheumatoid arthritis
Persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far from ideal in rheumatoid arthritis (RA) patients. An Ingress-Health team analyzed in a German claims data study both drug survival and therapy switches with regard to 2nd line bDMARD therapy in RA patients. Analysis was based on 451 patients receiving a second bDMARD (340 anti-TNF, mean age 52.6 years; 111 non-anti-TNF, mean age 55.9 years).
During the follow-up, 28.8% vs. 11.7% of the 2nd anti-TNF vs. non-anti-TNF patients (p < 0.001) switched to a 3rd bDMARD; 14.1% vs. 19.8% (p = 0.179) discontinued without re-start; 3.8% vs.1.8% (p = 0.387) re-started and 53.5 vs. 66.7% (p < 0.050) continued therapy. Patients in the non-anti-TNF group demonstrated longer drug survival (295 days) than patients in the anti-TNF group (264 days; p = 0.016).
To our knowledge, this is one of the first studies analyzing 2nd line drug survival of bDMARD therapy. It shows the strong the analytical skills the Ingress-Health team has to perform such studies.